Galapagos' last asset posts mixed results as future remains in flux

FierceBiotechHow Unlearn is building a scientific intelligence layer for clinical development

FierceBiotechHow AI is reshaping biopharma decision-making

FierceBiotechBiopharma IPOs: Timing, capital and staying flexible

Roche MediaRoche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - Pharmaceutical Technology

Endpoints NewsIncyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal

Endpoints NewsTakeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appeal

Endpoints NewsNurix to work with Roche on BTK degrader in deal worth up to $2.3B

FierceBiotechADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update

FierceBiotechRoche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown

BioPharma DiveInnovation alone is no longer enough in biopharma

BioPharma DivePrecision under pressure: Logistic solutions for nuclear medicine scalability

Lonza NewsLonza and Stipple Bio strike licensing deal for precision oncology ADCs - BioXconomy